Hosted on MSN2mon
FDA approves Azurity Pharmaceuticals’ Danziten for CML treatmentThe US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that does not require mealtime restrictions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback